The factsheet has been successfully sent.
Please check your inbox.
Favor proporcione sus datos para recibir la ficha informativa en su email
Enviar
Cancelar

0
Usted tienen ítems en la lista de mayor información
Solicitar la información ahora

14 July 2025 [Comunicado de prensa]

Group B Streptococcus (GBS) Awareness Month

July is Group B Streptococcus (GBS) Awareness Month, a time to promote awareness and prevention of this potentially life-threatening infection. According to the World Health Organization (WHO), each year nearly 20 million pregnant women carry GBS. Although harmless for most pregnant individuals, it can be extremely serious when it passes to babies during pregnancy, childbirth or in the first months of life. GBS can cause miscarriage, still or premature birth, sickness, lifelong handicaps, or even death. 

Universal GBS screening is now the standard of care in many countries. Accurate testing between 36 and 37 weeks of each pregnancy allows timely administration of intrapartum antibiotic prophylaxis (IAP) to identified carriers during labor. 

The GenoQuest GBS qPCR Assay can be completed in less than 2 hours and provides a highly sensitive method to detect as low as 30 copies of GBS DNA, and has been optimised for a fully automated workflow on the geneLEAD VIII system. If you would like to learn more about this platform, please contact our sales team at [email protected].

Acerca de DiagCor

Ubicados en Hong Kong, DiagCor se ha dedicado al desarrollo de pruebas moleculares (MDx) desde el 2006. Como líderes mundiales de la tecnología de hibridación rápida (flow-through hybridization), nuestra compañía ofrece una amplia gama de productos, soluciones y servicios relacionados con el análisis de ADN y ARN. Así mismo proveemos servicios de laboratorio MDx a médicos y profesionales en Asia Pacífica. DiagCor desarrolla y fabrica productos y soluciones MDx y a su vez ofrece consultoría en medicina translacional para proyectos MDx.



Contacto de prensa

DiagCor Life Science

[email protected]